Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 2/20 | 0.33 |
| ▸ | GABRD | O14764 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.33 |
| ▸ | GABRE | P78334 | 2/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.33 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.33 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.33 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6126 | 0.79 | GABRP (0.46) | ESR2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL873565 | 0.78 | — | — | |
| SCHEMBL28081306 | 0.76 | ESR2 (0.38) | ESR2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL28040988 | 0.75 | — | — | |
| SCHEMBL28050407 | 0.75 | — | — | |
| SCHEMBL873874 | 0.73 | — | — | |
| SCHEMBL873570 | 0.73 | CES2 (0.67) | CES2CES1 | |
| SCHEMBL1148096 | 0.72 | SMN1; SMN2 (0.40) | ESR2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL3626745 | 0.72 | ESR2 (0.35) | ESR2GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL3820477 | 0.72 | ESR2 (0.35) | ESR2GABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3564204-A1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | The University of Tokyo (JP) | 2019-11-06 | — | — | EP | disclosed |
| EP-3564204-A1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | The University of Tokyo (JP) | 2019-11-06 | — | — | EP | disclosed |
| EP-3045445-B1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | UNIV TOKYO (JP) | 2019-08-07 | — | — | EP | disclosed |
| EP-3045445-B1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | UNIV TOKYO (JP) | 2019-08-07 | — | — | EP | disclosed |
| EP-2606021-B1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | UNIV TOKYO (JP) | 2019-07-31 | — | — | EP | disclosed |
| EP-2606021-B1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | UNIV TOKYO (JP) | 2019-07-31 | — | — | EP | disclosed |
| EP-3045445-A1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | THE UNIVERSITY OF TOKYO (JP) | 2016-07-20 | — | — | EP | disclosed |
| US-9359279-B2 | Treatment of cancer, inflammatory disease, and autoimmune disease | ALLIANZ PHARMASCIENCE LTD. (TW) | 2016-06-07 | — | — | US | disclosed |
| US-9359279-B2 | Treatment of cancer, inflammatory disease, and autoimmune disease | ALLIANZ PHARMASCIENCE LTD. (TW) | 2016-06-07 | — | — | US | disclosed |
| US-9359279-B2 | Treatment of cancer, inflammatory disease, and autoimmune disease | ALLIANZ PHARMASCIENCE LTD. (TW) | 2016-06-07 | — | — | US | disclosed |
| US-20140371177-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASE, AND AUTOIMMUNE DISEASE | ALLIANZ PHARMASCIENCE LTD. (TW) | 2014-12-18 | — | — | US | disclosed |
| US-8822732-B2 | 1,5-diphenyl-penta-1,4-dien-3-one compounds | ANDROSCIENCE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822732-B2 | 1,5-diphenyl-penta-1,4-dien-3-one compounds | ANDROSCIENCE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822732-B2 | 1,5-diphenyl-penta-1,4-dien-3-one compounds | ANDROSCIENCE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| EP-2606021-A2 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | The University of Tokyo (JP) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012024282-A2 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | SHIH CHARLES C-Y (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012024282-A2 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | SHIH CHARLES C-Y (US) | 2012-02-23 | — | — | WO | disclosed |
| US-20120046247-A1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | ALLIANZ PHARMASCIENCE LTD. (TW) | 2012-02-23 | — | — | US | disclosed |
| US-20120046247-A1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | ALLIANZ PHARMASCIENCE LTD. (TW) | 2012-02-23 | — | — | US | disclosed |
| US-20120046247-A1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | ALLIANZ PHARMASCIENCE LTD. (TW) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046247-A1 | 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS | PDCD5, IL5, MALT1 | ESR2 1356/4885CES2 4831/4885CES1 1946/4885 |
| US-20140371177-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASE, AND AUTOIMMUNE DISEASE | PHOSPHO1, SELENOI, CD2 | ESR2 876/4885CES2 4060/4885CES1 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.